Analysis of various mRNA potentially involved in cisplatin resistance of murine leukemia L1210 cells.

PubMed ID: 1974166

Author(s): Sheibani N, Eastman A. Analysis of various mRNA potentially involved in cisplatin resistance of murine leukemia L1210 cells. Cancer Lett. 1990 Jul 31;52(3):179-85. PMID 1974166

Journal: Cancer Letters, Volume 52, Issue 3, Jul 1990

Enhanced DNA repair has been identified as a major mechanism of resistance to the anticancer drug cisplatin in murine leukemia L1210 cells. Studies of other cells have implicated the elevation of a variety of RNA transcripts in cisplatin resistance. This study investigated potential changes in transcription of these genes as well as genes involved in DNA repair. No elevation in any of the following transcripts was observed: thymidylate synthase, dihydrofolate reductase, DNA polymerase alpha, DNA polymerase beta, topoisomerase II, Ha-ras, beta-tubulin, metallothionein and the DNA repair genes ERCC1 and ERCC2. Thymidine kinase was increased no more than 2-fold. None of these RNA were induced by incubation with cisplatin. High levels of cisplatin produced selective decreases in certain RNA. These results demonstrate that the previous observations of elevated RNA can not be universally applied to all cisplatin-resistant cells.